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SMVT, a sodium-dependent multivitamin transporter, was
cloned in our laboratory ¢rst from rat placenta (Prasad et al,
1998) and subsequently from human placenta (Wang et al, 1999)
and rabbit intestine (Prasad et al, 1999). This transporter mediates
the active transport of three di¡erent water-soluble vitamins,
namely biotin, pantothenate, and lipoate and the transport pro-
cess is energized by a transmembrane electrochemical Naþ gradi-
ent (Prasad and Ganapathy, 2000). The Kt (Michaelis-Menten
constant) values for biotin and pantothenate for transport via hu-
man SMVT are B5 and B2mM, respectively.While the Kt value
for pantothenate is only about 20 times higher than the plasma
levels of this vitamin (B0.1 mM), the Kt value for biotin is four
orders of magnitude higher than the plasma levels of biotin.
The concentration of biotin in human blood is in the range of
0.5^2 nM (Mock et al, 1995). This raises the question as to whether
SMVTcan mediate the cellular uptake of biotin from the circula-
tion e⁄ciently at normal physiological concentrations of biotin. It
was purely coincidental that in the same year that we cloned
SMVT, Zempleni and Mock (1998) reported on the characteristics
of biotin uptake in peripheral blood mononuclear cells which in-
dicated the presence of a biotin transporter di¡erent from SMVT.
The transporter in immune cells is Na7dependent as is SMVT,
but the Kt value for biotin in the case of the new transporter is
B2.5 nM. Moreover, the transporter in immune cells does not
interact with pantothenate or lipoate. Thus, the newly identi¢ed
transporter is speci¢c for biotin and operates with an a⁄nity close
to the plasma levels of biotin. This transporter is induced in im-
mune cells during mitogen-induced proliferation (Zempleni and
Mock, 2000). Interestingly, SMVT is also expressed in immune
cells. Mock and his coworkers have hypothesized that while
SMVT is needed in these cells for the cellular uptake of pantothe-
nate, the newly identi¢ed transporter is predominantly responsi-
ble for biotin uptake under normal conditions (Zempleni and
Mock, 2000). That the biotin-speci¢c transporter identi¢ed in
immune cells is distinct from SMVT is further substantiated by
a recent report (Mardach et al, 2002) in which a biotin transport
defect was seen in peripheral blood mononuclear cells in a patient
associated with biotin dependency. The patient had no noticeable
defect in the functional activity of SMVT.
Until now, the novel high-a⁄nity biotin-selective transporter
had not been described in any tissue or cell type other than im-
mune cells. The report by Grafe et al in the current issue of the
Journal of Investigative Dermatology describes the presence of a bio-
tin-speci¢c transporter in human keratinocytes. This transporter
is Na7coupled, has a Kt value of B2.5 nM for biotin, and does
not interact with pantothenate or lipoate. These characteristics are
strikingly similar to those described for the high-a⁄nity biotin-
selective transporter in immune cells. It is very likely that the
same transporter is expressed in keratinocytes and immune cells.
The identi¢cation of a transporter in keratinocytes, that most
likely functions as the primary route for the cellular uptake
of biotin under physiological conditions, is of important clinical
relevance because the ¢rst symptoms to develop in biotin
de¢ciency are associated with the skin and hair (Mock, 1991). The
most common cutaneous ¢ndings include dry skin, seborrheic
dermatitis, erythematous rash, brittle hair, and alopecia. These
symptoms are followed by neurological complications if biotin
de¢ciency continues for longer periods. Biotin de¢ciency is not
uncommon (McMahon, 2002). There are several physiological,
pharmacological and pathological states in which biotin de¢-
ciency is seen. This includes under-nutrition, raw egg white in-
take, prolonged total parenteral nutrition, pregnancy, alcoholism,
treatment with antiepileptic medications such as phenytoin, pri-
midone, carbamazepine, and phenobarbitol, and genetic disorders
associated with defects in biotidinase involved in the recycling of
endogenous biotin. Therefore, a clear understanding of the cellu-
lar and molecular events involved in the delivery of biotin to keratin-
ocytes is clinically very relevant. The studies reported by
Grafe et al are the ¢rst to describe the uptake of biotin in keratin-
ocytes. These studies show quite convincingly that keratinocytes
express not only SMVT but also the high-a⁄nity biotin-selective
transporter. Under physiological conditions, the biotin-selective
transporter is most likely responsible for the delivery of biotin
from the circulation to the keratinocytes. In addition to this im-
portant physiological role, Grafe et al also suggest that the trans-
porter may serve a therapeutic role. These authors point out that
biotin is an ingredient in many of the popular pharmacological
and cosmetic products.When applied topically on the skin, biotin
is apparently well absorbed (Makino et al, 1999). The mechanisms
responsible for this absorption process have not been identi¢ed,
but it is quite probable that the newly described high-a⁄nity
biotin-selective transporter participates in this process.
While the functional identi¢cation of the high-a⁄nity biotin-
selective transporter in keratinocytes is clearly of physiological
and clinical relevance, a number of questions remain.To postulate
a potential role of this transporter in the delivery of biotin from
the circulation into the keratinocytes as well as in the absorption
of biotin from topically applied cosmetic or pharmacological
products, the exact localization of the transporter in these cells
needs to be established. If the transporter is expressed throughout
the plasma membrane of the keratinocytes, it would provide the
basis for its potential function in the above-mentioned biotin
absorptive processes. Additional studies are therefore needed to
demonstrate the localization of transporter at the protein level in
primary cultures of human keratinocytes as well as in native skin
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using immunological methods. Another issue is related to the
molecular identity of the transporter. There is no information
available in the literature on the identity of the gene or protein
that is responsible for the high-a⁄nity biotin-selective transporter
described in immune cells and keratinocytes. Mardach et al (2002)
have shown that there are no changes in the primary structure of
SMVT in the patient with a defect in the high-a⁄nity biotin-se-
lective transporter in immune cells. This may imply that the gene
coding for the biotin-selective transporter is di¡erent from the
gene coding for SMVT. However, the possibility exists that the
biotin-selective transporter may represent an alternative splice
variant of SMVT. The experimental approach employed by
Mardach et al (2002) does not rule out this possibility because
they generated the SMVT cDNA using RNA isolated from the
patient’s peripheral blood and then determined its sequence.While
this approach establishes that there are no mutations in the multi-
vitamin transporter in the patient, it does not address the issue of
alternative splicing of the gene contributing to the biotin-selec-
tive transporter. If a splice variant is responsible for the high-a⁄n-
ity biotin-selective transporter, it is possible that the patient with
a defect in the function of this transporter in immune cells may
have a defect in the splicing of the smvt gene. A recent report by
Gri⁄n et al (2002) has shown that a polyclonal antibody against
SMVT recognizes two di¡erent proteins on Western blot. The
molecular masses of the two proteins vary considerably (69 and
48 kDa).While the 69 kDa protein is likely to represent SMVT
based on its primary structure, the exact identity of the smaller
protein remains unknown. It would be interesting to see if there
is any functional relationship between the biotin-selective trans-
porter and the splice variants of the smvt gene.
Is the expression of the high-a⁄nity biotin-selective transpor-
ter unique to immune cells and keratinocytes? It is quite unlikely.
Based on the kinetic parameters, there is no doubt that SMVT
provides the transport mechanism for the delivery of pantothen-
ate into cells under physiological conditions.Whether SMVTcan
function e⁄ciently in the delivery of biotin into cells under nor-
mal conditions has been cast into doubt in the light of recent des-
cription of the high-a⁄nity biotin-selective transporter in
keratinocytes and immune cells.This newly identi¢ed transporter
is likely to be expressed in other cell types as well. Given the phys-
iological, pharmacological, and clinical relevance of this high-af-
¢nity biotin-selective transporter, further research is needed to
establish the molecular identity and the expression pattern of this
transporter.
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